[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 46 of about 46
1. Jung SW, Kwon YA, Lee MK, Song SW: Epidermophyton fungal keratitis following laser-assisted subepithelial keratectomy. J Cataract Refract Surg; 2009 Dec;35(12):2157-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment with conventional topical and systemic antibiotic agents did not improve the symptoms.
  • Treatment with topical amphotericin B was initiated, but there was little response.
  • After mycology culture and molecular analysis identified Epidermophyton floccosum as the infectious organism, topical natamycin was added and the infiltrate gradually resolved.
  • Treatment with topical natamycin was effective against Epidermophyton keratitis.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Tinea Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19969224.001).
  • [ISSN] 1873-4502
  • [Journal-full-title] Journal of cataract and refractive surgery
  • [ISO-abbreviation] J Cataract Refract Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 8O0C852CPO / Natamycin
  •  go-up   go-down


2. Gianoli F, Guex-Crosier Y, Marchetti O, Wolfensberger TJ, Spahn B: [Anterior segment necrosis in multidrug-resistant Fusarium keratomycosis: a case study]. J Fr Ophtalmol; 2005 May;28(5):498-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Predisposing factors in its pathogenesis are corneal trauma, mostly of plant origin, and overuse of topical corticosteroids, associated or not with antibiotics.
  • We report a case of a 71-year-old man who developed Fusarium (lichenicola or solani) keratitis, 15 days after beginning topical therapy with a corticosteroid and antibiotic.
  • Despite aggressive antifungal therapy with fluconazole, he required a penetrating keratoplasty for impending corneal perforation, and finally, even after systemic use of itraconazole and topical use of amphotericin B, the infection progressed and an evisceration was required.

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976716.001).
  • [ISSN] 0181-5512
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


3. Barnes SD, Dohlman CH, Durand ML: Fungal colonization and infection in Boston keratoprosthesis. Cornea; 2007 Jan;26(1):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Beginning in late 1999, many eyes were given a prophylactic topical regimen containing vancomycin, and many eyes with type 1 KPro were given therapeutic contact lenses.
  • The rate was higher in eyes receiving a vancomycin-containing topical prophylactic regimen than those with on a non-vancomycin regimen (5 cases/2774 person-months vs. 0 cases/4119 person-months; P = 0.011).
  • Cleaning or replacing the contact lens on a regular basis and prescribing a short course of topical amphotericin at the first visible signs of fungal colonization may prevent these infections.

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198007.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


Advertisement
4. Kaur IP, Kakkar S: Topical delivery of antifungal agents. Expert Opin Drug Deliv; 2010 Nov;7(11):1303-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical delivery of antifungal agents.
  • Topical therapy is the most favored form of treatment for these infections because it lends itself to self-administration, patient compliance, and absence of systemic adverse effects.
  • Several of these agents have a high molecular mass > 500 Da (such as amphotericin B, natamycin, or ketoconazole), resulting in their poor penetration (even if they are lipophilic in nature).
  • WHAT THE READER WILL GAIN: This article aims to discuss limitations to the topical therapy of antifungal agents, and delivery approaches used to enhance their effectiveness.
  • [MeSH-minor] Administration, Topical. Animals. Dermatomycoses / drug therapy. Drug Carriers / chemistry. Drug Design. Eye Infections, Fungal / drug therapy. Humans

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20961206.001).
  • [ISSN] 1744-7593
  • [Journal-full-title] Expert opinion on drug delivery
  • [ISO-abbreviation] Expert Opin Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Drug Carriers
  •  go-up   go-down


5. Capoor MR, Sarabahi S, Tiwari VK, Narayanan RP: Fungal infections in burns: Diagnosis and management. Indian J Plast Surg; 2010 Sep;43(Suppl):S37-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Burn wound infection (BWI) is a major public health problem and the most devastating form of trauma worldwide.
  • There is a need to speciate fungi as far as the topical and systemic antifungal is concerned.
  • Patients with FWC should be treated by aggressive surgical debridement and, in the case of fungal wound infection (FWI), in addition to surgical debridement, an intravenous antifungal drug, most commonly amphotericin B or caspofungin, is prescribed followed by de-escalating with voriconazole or itraconazole, or fluconazole depending upon the species or antifungal susceptibility, if available.
  • Therefore, the development of products to close the wound more rapidly, improvement in topical antifungal therapy with mould activity and implementation of appropriate systemic antifungal therapy guided by antifungal susceptibility may improve the outcome for severely injured burn victims.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Burn Care Rehabil. 1999 May-Jun;20(3):195-200 [10342470.001]
  • [Cites] J Hosp Infect. 1997 Dec;37(4):317-23 [9457609.001]
  • [Cites] East Mediterr Health J. 1999 Mar;5(2):333-6 [10793810.001]
  • [Cites] J Clin Microbiol. 2003 Apr;41(4):1440-6 [12682127.001]
  • [Cites] Surg Infect (Larchmt). 2002 Winter;3(4):367-74 [12697083.001]
  • [Cites] Mycopathologia. 2004 Nov;158(4):397-405 [15630548.001]
  • [Cites] Clin Microbiol Rev. 2006 Apr;19(2):403-34 [16614255.001]
  • [Cites] Burns. 2007 May;33(3):341-6 [17321689.001]
  • [Cites] Ann Surg. 2007 Jun;245(6):978-85 [17522525.001]
  • [Cites] J Burn Care Res. 2007 Nov-Dec;28(6):776-90 [17925660.001]
  • [Cites] J Burn Care Res. 2008 Jan-Feb;29(1):213-21 [18182925.001]
  • [Cites] J Burn Care Res. 2008 Mar-Apr;29(2):416-9 [18354306.001]
  • [Cites] Burns. 2008 Dec;34(8):1108-12 [18691821.001]
  • [Cites] ChemMedChem. 2009 Mar;4(3):310-23 [19170067.001]
  • [Cites] Clin Infect Dis. 2009 Mar 1;48(5):503-35 [19191635.001]
  • [Cites] Scand J Infect Dis. 2009;41(4):275-84 [19229762.001]
  • [Cites] Scand J Trauma Resusc Emerg Med. 2009;17:14 [19284591.001]
  • [Cites] Scand J Trauma Resusc Emerg Med. 2009;17:51; author reply 56 [19818134.001]
  • [Cites] Burns. 1998 Feb;24(1):72-3 [9601596.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1992 Sep;30(9):554-5, 573 [1307335.001]
  • [Cites] J Clin Microbiol. 2004 Aug;42(8):3456-61 [15297483.001]
  • [Cites] Infection. 1992 May-Jun;20(3):132-5 [1644487.001]
  • [Cites] Arch Surg. 1991 Jan;126(1):44-8 [1985634.001]
  • [Cites] J Clin Microbiol. 1986 Feb;23(2):258-61 [3084547.001]
  • [Cites] J Burn Care Rehabil. 1988 Nov-Dec;9(6):599-601 [3220866.001]
  • [Cites] J Trauma. 1979 Oct;19(10):765-7 [490691.001]
  • [Cites] Clin Microbiol Rev. 2000 Apr;13(2):236-301 [10756000.001]
  • (PMID = 21321655.001).
  • [ISSN] 1998-376X
  • [Journal-full-title] Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India
  • [ISO-abbreviation] Indian J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3038393
  • [Keywords] NOTNLM ; Burns / fungal infections / moulds / yeasts
  •  go-up   go-down


6. Mahdy RA, Nada WM, Wageh MM: Topical amphotericin B and subconjunctival injection of fluconazole (combination therapy) versus topical amphotericin B (monotherapy) in treatment of keratomycosis. J Ocul Pharmacol Ther; 2010 Jun;26(3):281-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical amphotericin B and subconjunctival injection of fluconazole (combination therapy) versus topical amphotericin B (monotherapy) in treatment of keratomycosis.
  • PURPOSE: The aim of the study was to compare the use of combination therapy of topical amphotericin B (0.5 mg/mL) eye drops together with subconjunctival injection of fluconazole (2 mg/mL) with the use of topical amphotericin B (0.5 mg/mL) eye drops alone in dealing with cases of fungal keratitis.
  • According to laboratory results, cases were classified into 2 groups: group 1 comprising 24 eyes treated by a combination therapy of topical amphotericin B eye drops (0.5 mg/mL) with subconjunctival injection of fluconazole (2 mg/mL) and group 2 comprising 24 eyes treated by topical amphotericin B eye drops (0.5 mg/mL) alone.
  • CONCLUSION: Combination therapy of topical amphotericin B eye drops with subconjunctival injection of fluconazole was more efficient (according to the percentage and the duration of healing of the ulcers) than the use of topical amphotericin B eye drops alone in dealing with cases of fungal keratitis--it may be contributed to the broad spectrum of the antifungal agents of the combination therapy than the monotherapy.
  • [MeSH-major] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Eye Infections, Fungal / drug therapy. Fluconazole / therapeutic use
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Candida / isolation & purification. Conjunctiva. Drug Therapy, Combination. Female. Follow-Up Studies. Fungi / isolation & purification. Humans. Injections. Keratitis / drug therapy. Keratitis / microbiology. Male. Middle Aged. Prospective Studies. Young Adult

  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20565316.001).
  • [ISSN] 1557-7732
  • [Journal-full-title] Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • [ISO-abbreviation] J Ocul Pharmacol Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole
  •  go-up   go-down


7. Mahdy RA, Nada WM, Wageh MM, Kader MA, Saleh MM, Alswad MM: Assessment safety and efficacy of a combination therapy of topical amphotericin B and subconjunctival fluconazole for the treatment of fungal keratitis. Cutan Ocul Toxicol; 2010 Sep;29(3):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment safety and efficacy of a combination therapy of topical amphotericin B and subconjunctival fluconazole for the treatment of fungal keratitis.
  • PURPOSE: The study was aimed at evaluating the treatment of fungal keratitis using a combination therapy of a low concentration of topical amphotericin B (0.2 mg/mL) eye drops together with subconjunctival injections of 2 mg/mL of fluconazole.
  • Topical amphotericin B eye drops in a concentration of 0.2 mg/mL in dextrose 5% were used every 2 hours for 21 days together with subconjunctival injections of fluconazole 2 mg/mL.
  • CONCLUSION: The use of a combination of topical amphotericin B eye drops at a concentration of 0.2 mg/mL in dextrose 5% with subconjunctival injection of fluconazole 2 mg/mL had the advantage of a lower incidence of the complications of local use of amphotericin B and a broader spectrum of antifungal coverage.
  • [MeSH-major] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Eye Infections, Fungal / drug therapy. Fluconazole / therapeutic use. Keratitis / drug therapy

  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20462395.001).
  • [ISSN] 1556-9535
  • [Journal-full-title] Cutaneous and ocular toxicology
  • [ISO-abbreviation] Cutan Ocul Toxicol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Ophthalmic Solutions; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole
  •  go-up   go-down


8. Park KA, Ahn K, Chung ES, Chung TY: Pichia anomala fungal keratitis. Cornea; 2008 Jun;27(5):619-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically, the organism appeared to respond to topical natamycin, amphotericine B, and oral itraconazole.
  • CONCLUSIONS: A rare case of P. anomala-associated keratitis was successfully treated with topical amphotericin B, natamycin, and systemic inidazole.
  • [MeSH-minor] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Drug Therapy, Combination. Female. Humans. Imidazoles / therapeutic use. Lupus Erythematosus, Systemic / complications. Middle Aged. Natamycin / therapeutic use. Stevens-Johnson Syndrome / complications

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520517.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Imidazoles; 7GBN705NH1 / imidazole; 7XU7A7DROE / Amphotericin B; 8O0C852CPO / Natamycin
  •  go-up   go-down


9. Usui T, Misawa Y, Honda N, Tomidokoro A, Yamagami S, Amano S: Nontraumatic keratomycosis caused by Alternaria in a glaucoma patient. Int Ophthalmol; 2009 Dec;29(6):529-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topical amphotericin B treatment achieved recovery from ulceration although the corneal opacity remained.

  • Genetic Alliance. consumer health - Glaucoma.
  • MedlinePlus Health Information. consumer health - Glaucoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Glaucoma. 2003 Dec;12 (6):480-5 [14646683.001]
  • [Cites] Mycoses. 2002 Dec;45(11-12):512-4 [12472731.001]
  • [Cites] Curr Opin Ophthalmol. 2004 Aug;15(4):321-7 [15232472.001]
  • [Cites] Cornea. 2002 Aug;21(6):555-9 [12131029.001]
  • [Cites] CLAO J. 2002 Jul;28(3):149-50 [12144235.001]
  • [Cites] CLAO J. 2001 Apr;27(2):111-2 [11352448.001]
  • [Cites] Am J Ophthalmol. 1975 May;79(5):881-2 [1170761.001]
  • [Cites] Am J Dermatopathol. 1996 Dec;18(6):611-3 [8989935.001]
  • (PMID = 18797820.001).
  • [ISSN] 1573-2630
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


10. Mohammad A, Al-Rajhi A, Wagoner MD: Trichophyton fungal keratitis. Cornea; 2006 Jan;25(1):118-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically, the organism seems to be sensitive to topical natamycin but resistant to topical amphotericin B and miconazole.

  • MedlinePlus Health Information. consumer health - Tinea Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331054.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents
  •  go-up   go-down


11. Jain V, Mhatre K, Nair AG, Shome D, Natarajan S: Aspergillus keratitis in vernal shield ulcer--a case report and review. Int Ophthalmol; 2010 Dec;30(6):641-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient was on topical steroids and anti-allergic treatment for the past two months.
  • The patient was treated with topical cyclosporine, topical moxifloxacin, topical natamycin, and topical amphotericin eye drops.
  • The chronic ocular surface changes and induced inflammation in VKC, and the instillation of topical steroids for therapy, may create an environmental milieu favorable for fungal keratitis.
  • This warrants patient education, periodic reviews and a very cautious approach to indiscriminate use of topical corticosteroids in cases of VKC with shield ulcer.
  • In the event of any secondary fungal infection, use of steroid sparing topical agent, for example cyclosporine may be considered.

  • Genetic Alliance. consumer health - Vernal keratitis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Ophthalmol. 2002 Sep;50(3):215-6 [12355698.001]
  • [Cites] Cornea. 1999 May;18(3):306-13 [10336034.001]
  • [Cites] Ann Ophthalmol. 1990 Oct;22(10):369-72 [2244717.001]
  • [Cites] Ophthalmology. 1994 Jun;101(6):1005-13 [8008340.001]
  • [Cites] Cornea. 2002 Mar;21(2):161-3 [11862086.001]
  • [Cites] Acta Ophthalmol Scand. 1999 Apr;77(2):229-31 [10321546.001]
  • [Cites] Acta Ophthalmol Scand. 2006 Jun;84(3):406-10 [16704708.001]
  • [Cites] Cornea. 2006 Sep;25(8):974-6 [17102679.001]
  • [Cites] Ophthalmology. 2000 Jun;107(6):1157-63 [10857837.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2007 Oct;7(5):424-8 [17873583.001]
  • [Cites] Cornea. 2003 Jan;22(1):80-1 [12502957.001]
  • [Cites] Cornea. 1992 Jul;11(4):355-9 [1424658.001]
  • [Cites] Ophthalmology. 1995 Jun;102(6):985-93 [7777308.001]
  • (PMID = 20127389.001).
  • [ISSN] 1573-2630
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Anti-Infective Agents; 0 / Antifungal Agents; 0 / Ophthalmic Solutions; 0 / Steroids
  •  go-up   go-down


12. Tuon FF, Costa SF: Rhodotorula infection. A systematic review of 128 cases from literature. Rev Iberoam Micol; 2008 Sep 30;25(3):135-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Amphotericin was the drug of choice in the treatment of fungemia and most of the eye infections were treated with topical amphotericin, although all patients lost their vision.

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18785780.001).
  • [ISSN] 1130-1406
  • [Journal-full-title] Revista iberoamericana de micología
  • [ISO-abbreviation] Rev Iberoam Micol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 72
  •  go-up   go-down


13. Goldblum D, Frueh BE, Sarra GM, Katsoulis K, Zimmerli S: Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model. Antimicrob Agents Chemother; 2005 Apr;49(4):1359-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model.
  • We compared the efficacy of topical caspofungin with that of topical amphotericin B (AMB) in a rabbit model of experimental keratomycosis.
  • In our rabbit model, 0.5% caspofungin was as effective as 0.15% AMB for the topical treatment of Candida keratitis.
  • [MeSH-minor] Administration, Topical. Amphotericin B / administration & dosage. Amphotericin B / therapeutic use. Animals. Candidiasis / drug therapy. Candidiasis / microbiology. Disease Models, Animal. Echinocandins. Humans. Male. Rabbits. Treatment Outcome

  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1116-21 [10752949.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Jun;40(7):1607-11 [10359345.001]
  • [Cites] Clin Infect Dis. 2001 Nov 1;33(9):1529-35 [11588698.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Feb;46(2):451-7 [11796357.001]
  • [Cites] Ophthalmic Res. 2002 Mar-Apr;34(2):97-103 [11914613.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Nov;46(11):3591-6 [12384370.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):2020-9 [12490683.001]
  • [Cites] Lancet. 2003 Oct 4;362(9390):1142-51 [14550704.001]
  • [Cites] Clin Microbiol Rev. 2003 Oct;16(4):730-97 [14557297.001]
  • [Cites] J Ocul Pharmacol. 1986 Fall;2(4):371-8 [3503121.001]
  • [Cites] Trans Am Ophthalmol Soc. 1990;88:685-725 [2095036.001]
  • [Cites] Ophthalmology. 1994 Jun;101(6):1005-13 [8008340.001]
  • [Cites] Cornea. 1997 Jan;16(1):64-71 [8985636.001]
  • [Cites] CLAO J. 1997 Oct;23(4):275-81 [9348453.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Mar;40(3):619-30 [10067965.001]
  • [Cites] Cornea. 2000 May;19(3):307-12 [10832689.001]
  • (PMID = 15793112.001).
  • [ISSN] 0066-4804
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Peptides, Cyclic; 7XU7A7DROE / Amphotericin B; F0XDI6ZL63 / caspofungin
  • [Other-IDs] NLM/ PMC1068631
  •  go-up   go-down


14. Niţulescu C: [Fungal keratitis--diagnostic and therapeutic approach]. Oftalmologia; 2006;50(4):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHOD: The paper presents a case of stromal fungal keratitis successfully treated with topical amphotericin B 0,2% and natamycin 5%.
  • [MeSH-minor] Adult. Amphotericin B / administration & dosage. Drug Therapy, Combination. Female. Humans. Microscopy, Acoustic. Natamycin / administration & dosage. Ophthalmic Solutions / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17345800.001).
  • [ISSN] 1220-0875
  • [Journal-full-title] Oftalmologia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Oftalmologia
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Ophthalmic Solutions; 7XU7A7DROE / Amphotericin B; 8O0C852CPO / Natamycin
  •  go-up   go-down


15. Zhao HM, Ran YP, Jiang X, Zeng W, Xiong L, Dai YL, Du XP, Yang G: [Isolation of Malassezia furfur from the groin abscess of a renal transplant patient]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jan;36(1):143-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient received oral fluconazole and topical amphotericin B.
  • The isolate before antifungal therapy was sensitive to both fluconazole and amphotericin B, while the isolate after antifungal treatment was only sensitive to amphotericin B.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15702803.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


16. Levy J, Benharroch D, Peled N, Lifshitz T: Blastoschizomyces capitatus keratitis and melting in a corneal graft. Can J Ophthalmol; 2006 Dec;41(6):772-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic fluconazole and systemic and topical amphotericin B treatment were started.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224964.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


17. Lee SJ, Lee JJ, Kim SD: Topical and oral voriconazole in the treatment of fungal keratitis. Korean J Ophthalmol; 2009 Mar;23(1):46-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical and oral voriconazole in the treatment of fungal keratitis.
  • The patient was treated with amphotericin but showed no signs of improvement.
  • Topical voriconazole, oral voriconazole, and intravitreal voriconazole yielded signs of improvement.
  • The second case is a 63-year-old male who underwent a month of empiric treatment with 0.2% topical amphotericin for fungal keratitis but showed no signs of improvement.

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):408-15 [12167683.001]
  • [Cites] Cornea. 2003 Jan;22(1):33-6 [12502945.001]
  • [Cites] Arch Ophthalmol. 2004 Jan;122(1):42-7 [14718293.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:183-9; discussion 189 [14971576.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):820-5 [15126145.001]
  • [Cites] J Ocul Pharmacol Ther. 2006 Dec;22(6):437-9 [17238810.001]
  • [Cites] Ophthalmic Surg. 1978 Dec;9(6):54-63 [311456.001]
  • [Cites] Korean J Ophthalmol. 2005 Mar;19(1):73-6 [15929491.001]
  • [Cites] Cornea. 2006 Feb;25(2):242-4 [16371794.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Jan;50(1):262-8 [16377696.001]
  • [Cites] Ophthalmology. 2006 Jul;113(7):1184-6 [16713628.001]
  • [Cites] Cornea. 2004 Jul;23(5):516-21 [15220739.001]
  • (PMID = 19337480.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Ophthalmic Solutions; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  • [Other-IDs] NLM/ PMC2655737
  • [Keywords] NOTNLM ; Fungus / Keratitis / Voriconazole
  •  go-up   go-down


18. Mundra RK, Gupta Y: Mucormycosis of nose and paranasal sinuses with orbital complication in young diabetic. Indian J Otolaryngol Head Neck Surg; 2008 Dec;60(4):360-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case report of mucormycosis of nose and paranasal sinuses with sudden loss of vision in a young diabetic with good recovery after endoscopic debridement, systemic and topical amphotericin B and control of Diabetes mellitus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1980 Apr;90(4):635-48 [7359982.001]
  • [Cites] Otolaryngol Clin North Am. 1993 Dec;26(6):1007-35 [8290280.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 May;124(5):520-6 [9604977.001]
  • [Cites] Otolaryngol Clin North Am. 2000 Apr;33(2):277-99 [10736404.001]
  • [Cites] Otolaryngol Clin North Am. 2000 Apr;33(2):349-65 [10736409.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1959 Mar;12(3):304-9 [13633228.001]
  • (PMID = 23120582.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3476816
  • [Keywords] NOTNLM ; Diabetes mellitus / Endoscopic debridement / Mucormycosis / Nose / Paranasal sinus
  •  go-up   go-down


19. Lupa M, Amedee R: Is topical amphotericin B efficacious in the treatment of chronic rhinosinusitis? Laryngoscope; 2010 Jun;120(6):1080-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is topical amphotericin B efficacious in the treatment of chronic rhinosinusitis?
  • [MeSH-major] Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Rhinitis / drug therapy. Sinusitis / drug therapy
  • [MeSH-minor] Administration, Topical. Chronic Disease. Humans. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Sinusitis.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20513020.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  • [Number-of-references] 5
  •  go-up   go-down


20. Pendleton RA, Holmes JH 4th: Systemic absorption of amphotericin B with topical 5% mafenide acetate/amphotericin B solution for grafted burn wounds: is it clinically relevant? Burns; 2010 Feb;36(1):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic absorption of amphotericin B with topical 5% mafenide acetate/amphotericin B solution for grafted burn wounds: is it clinically relevant?
  • OBJECTIVE: To determine if patients receiving topical amphotericin B in combination with 5% mafenide acetate solution will acquire systemically detectable levels of amphotericin B.
  • METHODS: A prospective, observational study of consecutive patients from May 2007 to March 2008 who received 5% mafenide acetate/amphotericin B (2 mcg/ml) solution topically every 4h to their excised and grafted burn wounds for at least 5 days.
  • Serum amphotericin B levels were measured every 5 days during treatment.
  • RESULTS: A total of 27 patients were enrolled, accumulating 420 treatment days and 72 amphotericin B levels.
  • Sixty-nine of the amphotericin B levels were undetectable, while 3 were detectable at non-therapeutic levels (<0.5 mcg/ml).
  • Of the patients with a detectable serum amphotericin B level, only one experienced adverse reactions that could potentially be attributed to amphotericin B.
  • The median duration of treatment was 8 days (range 5-52 days), and the median number of amphotericin B levels drawn per patient was 1 (range 1-19).
  • CONCLUSIONS: We conclude that 5% mafenide acetate/amphotericin B (2 mcg/ml) solution, applied to excised and grafted burn wounds, does not produce clinically relevant serum levels of amphotericin B.
  • Based on our observations, this topical regimen is safe.
  • [MeSH-major] Amphotericin B / blood. Anti-Infective Agents / blood. Burns / surgery. Mafenide / administration & dosage. Surgical Wound Infection / prevention & control

  • MedlinePlus Health Information. consumer health - Burns.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd and ISBI. All rights reserved.
  • (PMID = 19481350.001).
  • [ISSN] 1879-1409
  • [Journal-full-title] Burns : journal of the International Society for Burn Injuries
  • [ISO-abbreviation] Burns
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Anti-Infective Agents, Local; 0 / Drug Combinations; 58447S8P4L / Mafenide; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


21. Aydin S, Ertugrul B, Gultekin B, Uyar G, Kir E: Treatment of two postoperative endophthalmitis cases due to Aspergillus flavus and Scopulariopsis spp. with local and systemic antifungal therapy. BMC Infect Dis; 2007;7:87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was treated with topical amphotericin B ophthalmic solution, intravenous (IV) liposomal amphotericin-B and caspofungin following vitrectomy.
  • The patient was treated with topical and IV voriconazole and caspofungin.
  • [MeSH-minor] Aged. Amphotericin B / therapeutic use. Drug Therapy, Combination. Echinocandins / therapeutic use. Humans. Male. Pyrimidines / therapeutic use. Treatment Outcome. Triazoles / therapeutic use. Vitrectomy. Voriconazole

  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cornea. 2002 Oct;21(7):653-6 [12352080.001]
  • [Cites] Am J Ophthalmol. 2005 Sep;140(3):552-4 [16139017.001]
  • [Cites] Clin Experiment Ophthalmol. 2002 Dec;30(6):394-8 [12427228.001]
  • [Cites] Medicine (Baltimore). 2003 Mar;82(2):97-105 [12640186.001]
  • [Cites] Clin Infect Dis. 2000 Apr;30(4):696-709 [10770732.001]
  • [Cites] Indian J Ophthalmol. 2000 Jun;48(2):123-8 [11116508.001]
  • [Cites] Am J Ophthalmol. 2001 Nov;132(5):609-17 [11704021.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Jan;46(1):245-7 [11751145.001]
  • [Cites] Medicine (Baltimore). 2002 Jul;81(4):311-20 [12169886.001]
  • [Cites] Surv Ophthalmol. 2003 Jul-Aug;48(4):403-23 [12850229.001]
  • [Cites] Am J Ophthalmol. 2004 Jan;137(1):38-42 [14700642.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:183-9; discussion 189 [14971576.001]
  • [Cites] J Fr Ophtalmol. 2004 Mar;27(3):264-6 [15039628.001]
  • [Cites] Am J Ophthalmol. 2004 Apr;137(4):725-31 [15059712.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):820-5 [15126145.001]
  • [Cites] Arch Ophthalmol. 1980 Jun;98(6):1025-39 [7190003.001]
  • [Cites] Mycopathologia. 1981 May 8;74(2):125-7 [6787430.001]
  • [Cites] Am J Ophthalmol. 1985 Sep 15;100(3):408-10 [4037026.001]
  • [Cites] Ophthalmology. 1988 Jan;95(1):19-30 [3257818.001]
  • [Cites] J Infect Dis. 1990 Jul;162(1):115-20 [2355187.001]
  • [Cites] Infect Dis Clin North Am. 1995 Mar;9(1):1-9 [7769211.001]
  • [Cites] Am J Ophthalmol. 1996 Jul;122(1):1-17 [8659579.001]
  • [Cites] Diabet Med. 1996 May;13(5):457-63 [8737028.001]
  • [Cites] Clin Infect Dis. 1996 Feb;22(2):222-7 [8838176.001]
  • [Cites] Ophthalmic Surg Lasers. 1997 Mar;28(3):185-94 [9076791.001]
  • [Cites] Retina. 1997;17(3):256-8 [9196940.001]
  • [Cites] Ophthalmology. 1998 Mar;105(3):522-6 [9499785.001]
  • [Cites] Surv Ophthalmol. 1998 Nov-Dec;43(3):193-224 [9862309.001]
  • [Cites] Am J Ophthalmol. 1999 Aug;128(2):240-2 [10458187.001]
  • [Cites] J Antimicrob Chemother. 2004 Nov;54(5):854-69 [15375111.001]
  • [Cites] Am J Ophthalmol. 2005 Jan;139(1):135-40 [15652837.001]
  • [Cites] J Infect. 2002 Oct;45(3):184-95 [12387776.001]
  • (PMID = 17672897.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Pyrimidines; 0 / Triazoles; 7XU7A7DROE / Amphotericin B; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  • [Other-IDs] NLM/ PMC1950509
  •  go-up   go-down


22. Ozturk F, Yavas GF, Kusbeci T, Cetinkaya Z, Inan UU, Ermis SS, Kiraz N: Efficacy of topical caspofungin in experimental fusarium keratitis. Cornea; 2007 Jul;26(6):726-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of topical caspofungin in experimental fusarium keratitis.
  • PURPOSE: To evaluate the efficacy of caspofungin in an experimental rabbit model of Fusarium keratitis and to compare it with amphotericin B.
  • The first group received topical amphotericin B 0.15%, the second group received topical caspofungin 1%, and the control group received topical balanced salt solution hourly for 2 days and then 4 times daily for 3 additional days.
  • CONCLUSIONS: Topical caspofungin is effective in Fusarium keratitis, and clinical efficacy studies seem justified.
  • [MeSH-minor] Administration, Topical. Amphotericin B / administration & dosage. Amphotericin B / therapeutic use. Animals. Disease Models, Animal. Echinocandins. Rabbits. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592325.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Peptides, Cyclic; 7XU7A7DROE / Amphotericin B; F0XDI6ZL63 / caspofungin
  •  go-up   go-down


23. Gerlinger I, Fittler A: In reference to The Effect of Topical Amphotericin B on Inflammatory Markers in Patients with Chronic Rhinosinusitis: A Multicenter Randomized Controlled Study. Laryngoscope; 2010 Jan;120(1):210-2; author reply 213-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In reference to The Effect of Topical Amphotericin B on Inflammatory Markers in Patients with Chronic Rhinosinusitis: A Multicenter Randomized Controlled Study.
  • [MeSH-major] Amphotericin B / administration & dosage. Biomarkers / analysis. Inflammation / metabolism. Sinusitis / metabolism
  • [MeSH-minor] Administration, Topical. Humans. Multicenter Studies as Topic. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Sinusitis.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Laryngoscope. 2009 Feb;119(2):401-8 [19160404.001]
  • (PMID = 19653265.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


24. Wu PC, Lai CH, Tan HY, Ma DH, Hsiao CH: The successful medical treatment of a case of Paecilomyces lilacinus keratitis. Cornea; 2010 Mar;29(3):357-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report the successful medical treatment of Paecilomyces lilacinus keratitis case with topical voriconazole.
  • Infection was progressive despite initial treatment with hourly topical amphotericin B (1.5 mg/mL) and topical 5% natamycin.
  • Treatment was switched to hourly topical voriconazole (10 mg/mL).
  • RESULTS: The infection responded well to topical voriconazole and resolved within 1 month without any surgical intervention.
  • [MeSH-minor] Administration, Topical. Aged. Humans. Male. Voriconazole

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098311.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  •  go-up   go-down


25. Mehta H, Mehta HB, Garg P, Kodial H: Voriconazole for the treatment of refractory Aspergillus fumigatus keratitis. Indian J Ophthalmol; 2008 May-Jun;56(3):243-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She was started on topical natamycin eye drops, but the infiltrate continued to progress.
  • Topical amphotericin B and systemic ketoconazole was added, however, there was no response and the infiltrate increased further.
  • She was then switched to topical and systemic voriconazole.

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2000 Mar;107(3):574-80 [10711898.001]
  • [Cites] Br J Ophthalmol. 2000 Aug;84(8):932-3 [10979655.001]
  • [Cites] Clin Infect Dis. 2002 Mar 1;34(5):563-71 [11807679.001]
  • [Cites] Cornea. 2002 Aug;21(6):555-9 [12131029.001]
  • [Cites] Arch Ophthalmol. 2003 May;121(5):735-7 [12742860.001]
  • [Cites] Arch Ophthalmol. 2004 Jan;122(1):42-7 [14718293.001]
  • [Cites] Arch Ophthalmol. 2007 Jun;125(6):789-93 [17562990.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):820-5 [15126145.001]
  • [Cites] Curr Opin Ophthalmol. 2004 Aug;15(4):321-7 [15232472.001]
  • [Cites] Retina. 2006 Oct;26(8):935-9 [17031296.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Jan;51(1):239-44 [17060517.001]
  • [Cites] Am J Ophthalmol. 2007 Jan;143(1):151-3 [17188052.001]
  • [Cites] Indian J Ophthalmol. 2003 Dec;51(4):315-21 [14750619.001]
  • (PMID = 18417831.001).
  • [ISSN] 0301-4738
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  • [Other-IDs] NLM/ PMC2636104
  •  go-up   go-down


26. Shirazi MA, Stankiewicz JA, Kammeyer P: Activity of nasal amphotericin B irrigation against fungal organisms in vitro. Am J Rhinol; 2007 Mar-Apr;21(2):145-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of nasal amphotericin B irrigation against fungal organisms in vitro.
  • Controversy exists on the use of topical amphotericin B therapy as a treatment modality for this condition.
  • The effect of various concentrations of amphotericin B nasal irrigation on actively growing fungi was studied in vitro.
  • Each fungi was exposed to 20 mL of amphotericin B nasal irrigation at concentrations of either 100, 200, or 300 microg/mL or sterile water two times daily for 6 weeks.
  • RESULTS: Fungi growth was not arrested in the 100-microg/mL amphotericin B and sterile water groups at the end of 6 weeks.
  • Use of the 300-and 200-microg/mL amphotericin B solutions showed failure of the subcultured fungi to grow at 5 and 6 weeks, respectively.
  • CONCLUSION: Nasal amphotericin B irrigation is ineffective in killing fungi in vitro at a concentration of 100 microg/mL over a 6-week period.
  • The current concentration of commercially available topical amphotericin B (100 microg/mL) seems ineffective in eradicating fungi in vitro.
  • [MeSH-major] Amphotericin B / pharmacology. Antifungal Agents / pharmacology. Fungi / drug effects. Nasal Cavity / microbiology

  • MedlinePlus Health Information. consumer health - Molds.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17424868.001).
  • [ISSN] 1050-6586
  • [Journal-full-title] American journal of rhinology
  • [ISO-abbreviation] Am J Rhinol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


27. Rautemaa R, Richardson M, Pfaller MA, Perheentupa J, Saxén H: Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. Diagn Microbiol Infect Dis; 2008 Oct;62(2):182-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
  • Antifungal activity of amphotericin B, echinocandins, and azoles was determined by the Clinical and Laboratory Standards Institute M27-A2 methodology.
  • All isolates were highly susceptible to amphotericin B and echinocandins.
  • Our data suggest that topical amphotericin B could continue to be a safe and active drug for daily administration for APECED patients.
  • [MeSH-minor] Amphotericin B / pharmacology. Azoles / administration & dosage. Azoles / pharmacology. Azoles / therapeutic use. Echinocandins / pharmacology. Finland. Humans. Microbial Sensitivity Tests / methods. Microbial Sensitivity Tests / statistics & numerical data. Time Factors


28. Yavas GF, Oztürk F, Küsbeci T, Cetinkaya Z, Ermis SS, Kiraz N, Inan UU: Antifungal efficacy of voriconazole, itraconazole and amphotericin b in experimental fusarium solani keratitis. Graefes Arch Clin Exp Ophthalmol; 2008 Feb;246(2):275-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antifungal efficacy of voriconazole, itraconazole and amphotericin b in experimental fusarium solani keratitis.
  • PURPOSE: To evaluate the efficacy of topical voriconazole in an experimental rabbit model of Fusarium keratitis.
  • Group 1 received topical amphotericin B 0.15%, group 2 received topical itraconazole 1% and group 3 received topical voriconazole 1% hourly between 08:00 to 22:00 on days 1 and 2; 4 times daily on days 3-5.
  • Control group received topical balanced salt solution at identical intervals.
  • Culture was sterile in the group receiving amphotericin B.
  • As a result, itraconazole 1% and voriconazole 1% were found to be effective in Fusarium keratitis clinically and microbiologically, although their activity was not as effective as amphotericin B 0.15%.
  • [MeSH-minor] Administration, Topical. Amphotericin B / administration & dosage. Animals. Colony Count, Microbial. Itraconazole / administration & dosage. Pyrimidines / administration & dosage. Rabbits. Treatment Outcome. Triazoles / administration & dosage. Voriconazole

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. Itraconazole .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Ocul Pharmacol Ther. 2006 Dec;22(6):437-9 [17238810.001]
  • [Cites] Br J Ophthalmol. 2002 Nov;86(11):1211-5 [12386069.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2634-43 [12766067.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Feb;10(2):73-90 [14750074.001]
  • [Cites] Acta Ophthalmol Scand. 2004 Dec;82(6):762-4 [15606478.001]
  • [Cites] Cornea. 2002 Aug;21(6):555-9 [12131029.001]
  • [Cites] Ophthalmologe. 1995 Aug;92(4):469-75 [7549331.001]
  • [Cites] Clin Infect Dis. 2005 Jun 15;40(12):e110-2 [15909252.001]
  • [Cites] Am J Ophthalmol. 2005 Sep;140(3):552-4 [16139017.001]
  • [Cites] Am J Ophthalmol. 2005 Sep;140(3):454-8 [16026751.001]
  • [Cites] Int J Clin Pract. 2005 May;59(5):549-54 [15857351.001]
  • [Cites] Indian J Ophthalmol. 2001 Sep;49(3):173-6 [15887725.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1998 Aug;17(8):573-5 [9796657.001]
  • [Cites] Br J Ophthalmol. 2000 Aug;84(8):932-3 [10979655.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):820-5 [15126145.001]
  • [Cites] Clin Microbiol Infect. 2004 Sep;10(9):773-6 [15355406.001]
  • [Cites] Cornea. 2005 May;24(4):449-52 [15829804.001]
  • [Cites] J Environ Sci Health B. 2001 May;36(3):331-40 [11411855.001]
  • [Cites] Am J Ophthalmol. 2007 Jan;143(1):151-3 [17188052.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3623-6 [12904365.001]
  • (PMID = 17912543.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 304NUG5GF4 / Itraconazole; 7XU7A7DROE / Amphotericin B; JFU09I87TR / Voriconazole
  •  go-up   go-down


29. Klont RR, Eggink CA, Rijs AJ, Wesseling P, Verweij PE: Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis; 2005 Jun 15;40(12):e110-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole.
  • A case of invasive Fusarium keratitis in a previously healthy male patient was treated successfully with cornea transplantation and systemic and topical voriconazole after treatment failure with topical amphotericin B and systemic itraconazole.
  • Topical voriconazole was well tolerated, and, in conjunction with the oral administration, it resulted in a high level of the drug in the anterior chamber of the eye (which was 160% of the plasma drug level).
  • [MeSH-minor] Adult. Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Cornea / pathology. Humans. Itraconazole / therapeutic use. Male. Voriconazole

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. Itraconazole .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909252.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 304NUG5GF4 / Itraconazole; 7XU7A7DROE / Amphotericin B; JFU09I87TR / Voriconazole
  •  go-up   go-down


30. Touvron G, Denis D, Doat M, Girard A, Brandely ML, Chast F, Renard G: [Successful treatment of resistant Fusarium solani keratitis with liposomal amphotericin B]. J Fr Ophtalmol; 2009 Dec;32(10):721-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of resistant Fusarium solani keratitis with liposomal amphotericin B].
  • The infection regressed with topical amphotericin B and intravenous voriconazole.
  • Topical steroids were introduced.
  • Recovery was achieved without surgery, with topical voriconazole, topical liposomal amphotericin B, topical natamycin, intravenous liposomal amphotericin B, and intravenous voriconazole.
  • Liposomal amphotericin B seems to be the most effective drug for the different infection stages.
  • [MeSH-major] Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Eye Infections, Fungal / drug therapy. Fusarium. Keratitis / drug therapy. Keratitis / microbiology. Mycoses / drug therapy

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19942316.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Liposomes; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


31. Ebbens FA, Georgalas C, Luiten S, van Drunen CM, Badia L, Scadding GK, Hellings PW, Jorissen M, Mullol J, Cardesin A, Bachert C, van Zele TP, Lund VJ, Fokkens WJ: The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: a multicenter randomized controlled study. Laryngoscope; 2009 Feb;119(2):401-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: a multicenter randomized controlled study.
  • Based on this rationale, the use of topical antifungals (amphotericin B) has been advocated.
  • METHODS: Part two of a prospective double-blind, placebo-controlled multicenter clinical trial investigating the effect of 13 weeks of treatment with amphotericin B or placebo on the levels of pro-inflammatory cytokines, chemokines and growth factors (i.e., IL-1beta, IL-1RA, IL-2, IL-2R, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40/p70 subunits), IL-13, IL-15, IL-17, TNF-alpha, IFN-alpha, IFN-gamma, G-CSF, GM-CSF, MIP-1alpha, MIP-1beta, IP-10, MIG, eotaxin, RANTES, MCP-1, MCP-2, MCP-3, VEGF, EGF, FGF-basic, HGF, Gro-alpha) and albumin via a fluorescent enzyme immunoassay in nasal lavage specimens of CRS patients with or without NP.
  • RESULTS: Topical amphotericin B had no significant effect on the level of any of the tested pro-inflammatory cytokines, chemokines, and growth factors in CRS nasal lavage samples.
  • CONCLUSIONS: Topical amphotericin B has no significant effect on activation markers of nasal inflammatory cells in chronic rhinosinusitis with or without nasal polyps.
  • [MeSH-major] Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Rhinitis / drug therapy. Sinusitis / drug therapy
  • [MeSH-minor] Administration, Intranasal. Administration, Topical. Adult. Chemokines / analysis. Chi-Square Distribution. Chronic Disease. Cytokines / analysis. Double-Blind Method. Female. Humans. Inflammation / drug therapy. Intercellular Signaling Peptides and Proteins / analysis. Male. Middle Aged. Nasal Lavage. Nasal Polyps / drug therapy. Nasal Polyps / microbiology. Prospective Studies. Statistics, Nonparametric. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Sinusitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Laryngoscope. 2010 Jan;120(1):210-2; author reply 213-4 [19653265.001]
  • (PMID = 19160404.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Chemokines; 0 / Cytokines; 0 / Intercellular Signaling Peptides and Proteins; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


32. Yoon S, Kim S, Lee KA, Kim H: [A case of Scedosporium apiospermum keratitis confirmed by a molecular genetic method]. Korean J Lab Med; 2008 Aug;28(4):307-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He had been treated with topical and oral antibacterial in addition to antifungal agents, but did not show significant clinical improvement.
  • After a positive corneal culture with mold, topical amphotericin B was added to the initial regimen.
  • The mold was identified as Scedosporium apiospermum by macroscopic and microscopic morphologies and the nucleotide sequences of a fungal PCR product showing 99% homology with those of S. apiospermum (EF151349).
  • [MeSH-minor] Amphotericin B / therapeutic use. Anti-Bacterial Agents / therapeutic use. Antifungal Agents / therapeutic use. Cornea / microbiology. Drug Therapy, Combination. Humans. Male. Middle Aged. Polymerase Chain Reaction. Sequence Analysis, DNA

  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728381.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


33. Farjo QA, Farjo RS, Farjo AA: Scytalidium keratitis: case report in a human eye. Cornea; 2006 Dec;25(10):1231-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although initially culture negative and responsive to topical steroids, the keratitis persisted, and repeat corneal scrapings and cultures revealed Scytalidium species.
  • Treatment with topical amphotericin B 0.15% and oral fluconazole 200 mg twice daily eradicated the infection, and the patient had a final best-corrected visual acuity of 20/20.
  • Intensive oral and topical antifungal therapy was successful in eradicating the infection.
  • [MeSH-minor] Administration, Oral. Administration, Topical. Adult. Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Drug Therapy, Combination. Female. Fluconazole / therapeutic use. Humans

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172905.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole
  •  go-up   go-down


34. Jurkunas U, Behlau I, Colby K: Fungal keratitis: changing pathogens and risk factors. Cornea; 2009 Jul;28(6):638-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of patients (70%) received oral antifungal treatment in addition to topical amphotericin B and natamycin.
  • [MeSH-minor] Administration, Oral. Administration, Topical. Adult. Aged. Alternaria. Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Antifungal Agents / adverse effects. Boston / epidemiology. Candidiasis. Cohort Studies. Contact Lenses / adverse effects. Corneal Transplantation / statistics & numerical data. Drug Therapy, Combination. Female. Fusarium. Humans. Incidence. Male. Middle Aged. Natamycin / administration & dosage. Retrospective Studies. Risk Factors. Treatment Outcome

  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19512908.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B; 8O0C852CPO / Natamycin
  •  go-up   go-down


35. Kurnatowski P, Kurnatowska AK: [Treatment of fungal infections of upper respiratory tract and ear]. Otolaryngol Pol; 2007;61(3):280-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Physicians may prescribe antibiotics (mainly pollens: amphotericin B, natamycin and nystatin) and chemiotherapeutics (mainly azoles and fluorpirymidins, pigments, chlorhexidine and chlorquinaldol).
  • In ENT practice topical and systemic drugs can be administrated.
  • Topical lozenges include amphotericin B, clotrimazole, chlorhexidine or chlorquinaldol and oral gels: nystatin and miconazole.
  • Some of drugs are in the form of suspension/solution, which can be used for inhalation, into the sinus, for swabbing or for lavage: amphotericin B, natamycin, nystatin, clotrimazol, flucytosine, miconazole, fluconazole, vorykonazole, caspofungin.
  • [MeSH-minor] Administration, Inhalation. Administration, Oral. Administration, Topical. Amphotericin B. Azoles / administration & dosage. Azoles / therapeutic use. Clotrimazole. Humans. Miconazole. Nystatin. Otitis / drug therapy. Otitis / microbiology

  • MedlinePlus Health Information. consumer health - Ear Disorders.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. NYSTATIN .
  • Hazardous Substances Data Bank. CLOTRIMAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17847781.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Azoles; 1400-61-9 / Nystatin; 7NNO0D7S5M / Miconazole; 7XU7A7DROE / Amphotericin B; G07GZ97H65 / Clotrimazole
  • [Number-of-references] 19
  •  go-up   go-down


36. Lafleur MD, Qi Q, Lewis K: Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob Agents Chemother; 2010 Jan;54(1):39-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Persisters form upon attachment to a surface, an important step in the pathogenesis of Candida strains.
  • In order to test this possibility, 150 isolates of Candida albicans and C. glabrata were obtained from cancer patients who were at high risk for the development of oral candidiasis and who had been treated with topical chlorhexidine once a day.
  • Persister levels were measured by exposing biofilms growing in the wells of microtiter plates to high concentrations of amphotericin B and plating for survivors.
  • All of the high-persister isolates had an amphotericin B MIC that was the same as that for the wild type, indicating that these strains were drug-tolerant rather than drug-resistant mutants.

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CHLORHEXIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2007 Jan 1;195(1):149-57 [17152019.001]
  • [Cites] J Bacteriol. 2006 Dec;188(24):8360-7 [17041039.001]
  • [Cites] Antimicrob Agents Chemother. 2008 May;52(5):1884-7 [18285487.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Aug;52(8):2718-26 [18519731.001]
  • [Cites] BMC Microbiol. 2008;8:135 [18694525.001]
  • [Cites] Science. 2009 Jan 16;323(5912):396-401 [19150849.001]
  • [Cites] Am Clin Lab. 2001 Aug;20(7):42-4 [11570274.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Sep;45(9):2475-9 [11502517.001]
  • [Cites] Oral Microbiol Immunol. 2009 Jun;24(3):249-54 [19416456.001]
  • [Cites] J Bacteriol. 2001 Dec;183(23):6746-51 [11698361.001]
  • [Cites] Oral Microbiol Immunol. 2002 Apr;17(2):79-84 [11929553.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):774-7 [12354806.001]
  • [Cites] Trends Microbiol. 2003 Jan;11(1):30-6 [12526852.001]
  • [Cites] J Bacteriol. 1983 Aug;155(2):768-75 [6348026.001]
  • [Cites] Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):924-35 [3895958.001]
  • [Cites] J Bacteriol. 1986 May;166(2):399-403 [3516974.001]
  • [Cites] Genetics. 1993 Jul;134(3):717-28 [8349105.001]
  • [Cites] J Clin Microbiol. 1994 Aug;32(8):1923-9 [7989544.001]
  • [Cites] J Dent Res. 1995 May;74(5):1152-61 [7790592.001]
  • [Cites] J Clin Microbiol. 1996 Sep;34(9):2246-54 [8862593.001]
  • [Cites] J Bacteriol. 2004 Dec;186(24):8172-80 [15576765.001]
  • [Cites] Biochemistry (Mosc). 2005 Feb;70(2):267-74 [15807669.001]
  • [Cites] J Oral Pathol Med. 2005 Jul;34(6):352-6 [15946183.001]
  • [Cites] Med Mycol. 2005 May;43(3):191-208 [16010846.001]
  • [Cites] Annu Rev Microbiol. 2005;59:113-33 [16153165.001]
  • [Cites] J Bacteriol. 2006 Jul;188(14):5136-44 [16816185.001]
  • [Cites] Oral Oncol. 2006 Aug;42(7):698-702 [16527512.001]
  • [Cites] BMC Microbiol. 2006;6:53 [16768798.001]
  • [Cites] Lett Appl Microbiol. 2006 Sep;43(3):318-24 [16910939.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Nov;50(11):3839-46 [16923951.001]
  • [Cites] Nat Rev Microbiol. 2007 Jan;5(1):48-56 [17143318.001]
  • (PMID = 19841146.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM061162; United States / NIGMS NIH HHS / GM / 2R01GM061162-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mouthwashes; R4KO0DY52L / Chlorhexidine
  • [Other-IDs] NLM/ PMC2798516
  •  go-up   go-down


37. Ozbek Z, Kang S, Sivalingam J, Rapuano CJ, Cohen EJ, Hammersmith KM: Voriconazole in the management of Alternaria keratitis. Cornea; 2006 Feb;25(2):242-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A 69-year-old man with a history of corneal foreign body removal developed a stromal infiltrate 2 months later that did not improve despite topical antibiotics and natamycin.
  • VA decreased to 20/200, and increased inflammation was noted a month later; a trial of topical steroids was added.
  • Repeat culture revealed Alternaria species, and topical amphotericin was started.
  • When there was no response, he was admitted and switched to oral and topical voriconazole.
  • Although not approved for ophthalmic use yet, voriconazole provided improvement with Alternaria keratitis unresponsive to amphotericin.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371794.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Ophthalmic Solutions; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  •  go-up   go-down


38. Pariseau B, Nehls S, Ogawa GS, Sutton DA, Wickes BL, Romanelli AM: Beauveria keratitis and biopesticides: case histories and a random amplification of polymorphic DNA comparison. Cornea; 2010 Feb;29(2):152-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 55-year-old diabetic woman from New Mexico and a 31-year-old healthy woman from southern Wisconsin developed soft contact lens-related corneal ulcers unresponsive to topical moxifloxacin and prednisolone acetate drops.
  • RESULTS: Patient 1 responded to topical natamycin, ketoconazole, and 200 mg oral ketoconazole twice daily before developing a secondary bacterial infection requiring penetrating keratoplasty.
  • Patient 2 was treated with topical natamycin, topical amphotericin, and 200 mg oral voriconazole twice daily for 1 month with residual scarring and a best-corrected visual acuity of 20/25.

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023588.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE14318
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / DNA, Fungal; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  •  go-up   go-down


39. Patel SR, Hammersmith KM, Rapuano CJ, Cohen EJ: Exophiala dermatitidis keratitis after laser in situ keratomileusis. J Cataract Refract Surg; 2006 Apr;32(4):681-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This infection waxed and waned for 9 months despite therapy with natamycin, itraconazole, and fluconazole but eventually responded to topical amphotericin.
  • [MeSH-minor] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Humans. Male. Microbial Sensitivity Tests. Middle Aged. Myopia / surgery. Recurrence

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698496.001).
  • [ISSN] 0886-3350
  • [Journal-full-title] Journal of cataract and refractive surgery
  • [ISO-abbreviation] J Cataract Refract Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


40. Barodka VM, Acheampong E, Powell G, Lobach L, Logan DA, Parveen Z, Armstead V, Mukhtar M: Antimicrobial effects of liquid anesthetic isoflurane on Candida albicans. J Transl Med; 2006 Nov 09;4:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Candida albicans is a dimorphic fungus that can grow in yeast morphology or hyphal form depending on the surrounding environment.
  • In this study, we assessed the anti-candidal activity of the volatile anesthetic isoflurane in liquid form in comparison with the anti-fungal agent amphotericin B in an in vitro culture system.
  • These data suggest development of potential topical application of isoflurane for controlling a series of cutaneous and genital infections associated with this fungus.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Microbiol. 2003 Oct;50(2):391-409 [14617167.001]
  • [Cites] Gene. 1992 Nov 2;121(1):173-7 [1427093.001]
  • [Cites] Infect Immun. 2004 Feb;72(2):833-43 [14742527.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jul;48(7):2350-4 [15215080.001]
  • [Cites] Curr Opin Infect Dis. 2004 Aug;17(4):347-52 [15241080.001]
  • [Cites] Anesth Analg. 1992 May;74(5):747-52 [1567044.001]
  • [Cites] Crit Care Med. 2005 Mar;33(3):585-90 [15753751.001]
  • [Cites] Mol Biol Cell. 2005 Aug;16(8):3727-39 [15930127.001]
  • [Cites] Eukaryot Cell. 2005 Jul;4(7):1273-86 [16002653.001]
  • [Cites] Infect Dis Obstet Gynecol. 2005 Jun;13(2):63-7 [16011995.001]
  • [Cites] Br J Anaesth. 2005 Oct;95(4):530-4 [16040635.001]
  • [Cites] Can J Anaesth. 2005 Nov;52(9):951-7 [16251561.001]
  • [Cites] Mycoses. 2005 Nov;48(6):365-77 [16262871.001]
  • [Cites] Mol Biol Cell. 2006 Jan;17(1):295-307 [16267276.001]
  • [Cites] Anesth Analg. 2006 Jan;102(1):129-34 [16368817.001]
  • [Cites] Int J STD AIDS. 2006 Apr;17(4):260-6 [16595050.001]
  • [Cites] Biol Pharm Bull. 2006 May;29(5):919-22 [16651719.001]
  • [Cites] Pediatr Infect Dis J. 2006 Jul;25(7):655-6 [16804443.001]
  • [Cites] Histol Histopathol. 2006 Oct;21(10):1029-41 [16835826.001]
  • [Cites] J Med Vet Mycol. 1987 Feb;25(1):47-53 [3106612.001]
  • [Cites] J Gen Microbiol. 1985 Sep;131(9):2209-16 [3906035.001]
  • [Cites] J Appl Bacteriol. 1983 Aug;55(1):119-25 [6413475.001]
  • [Cites] Mol Cell Biol. 1982 Jul;2(7):853-62 [6765567.001]
  • [Cites] Sabouraudia. 1975 Jul;13(2):148-53 [808868.001]
  • [Cites] Anasthesiol Intensivmed Notfallmed Schmerzther. 1995 Dec;30(8):483-7 [8580241.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3446-53 [8668160.001]
  • [Cites] J Clin Microbiol. 1997 Sep;35(9):2320-4 [9276410.001]
  • [Cites] Anesth Analg. 1998 May;86(5):1075-8 [9585301.001]
  • [Cites] Curr Opin Microbiol. 1998 Dec;1(6):687-92 [10066539.001]
  • [Cites] Chemotherapy. 2000 May-Jun;46(3):219-28 [10765040.001]
  • [Cites] Eur J Anaesthesiol. 2000 May;17(5):289-94 [10926068.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Oct;44(10):2752-8 [10991856.001]
  • [Cites] J Bacteriol. 2001 May;183(10):3211-23 [11325951.001]
  • [Cites] Infect Immun. 2002 Jul;70(7):3689-700 [12065511.001]
  • [Cites] Genetics. 2002 Jun;161(2):563-74 [12072454.001]
  • [Cites] Int J Med Microbiol. 2002 Oct;292(5-6):299-311 [12452278.001]
  • [Cites] Med Mycol. 2003 Feb;41(1):43-52 [12627803.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14327-32 [14623979.001]
  • (PMID = 17094810.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH074359
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1664588
  •  go-up   go-down


41. Jhanji V, Sharma N, Mannan R, Titiyal JS, Vajpayee RB: Management of tunnel fungal infection with voriconazole. J Cataract Refract Surg; 2007 May;33(5):915-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no response to 6 weeks of therapy with topical fortified antibiotic agents and topical antifungal therapy in the form of natamycin 5%, amphotericin B 0.15%, and intracameral amphotericin B.
  • The patient was started on oral voriconazole 200 mg twice daily and topical voriconazole 1% every hour, and resolution of the ulcer was noted within 3 days.
  • This case illustrates that topical and oral voriconazole may be used in the treatment of recalcitrant cases of fungal tunnel infections not responding to conventional antifungal therapy.
  • [MeSH-minor] Administration, Oral. Administration, Topical. Aged. Cataract Extraction. Female. Humans. Microsurgery. Visual Acuity. Voriconazole

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cataract Refract Surg. 2008 Feb;34(2):183-4 [18242428.001]
  • (PMID = 17466872.001).
  • [ISSN] 0886-3350
  • [Journal-full-title] Journal of cataract and refractive surgery
  • [ISO-abbreviation] J Cataract Refract Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  •  go-up   go-down


42. Lifshitz T, Levy J: Rhodotorula rubra keratitis and melting after repeated penetrating keratoplasty. Eur J Ophthalmol; 2005 Jan-Feb;15(1):135-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic and topical amphotericin B treatment was started.
  • [MeSH-minor] Abscess / microbiology. Abscess / surgery. Aged. Amphotericin B / therapeutic use. Corneal Diseases / microbiology. Corneal Diseases / surgery. Dexamethasone / therapeutic use. Drug Therapy, Combination / therapeutic use. Humans. Male. Ofloxacin / therapeutic use. Recurrence. Reoperation

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. Ofloxacin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751254.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 7XU7A7DROE / Amphotericin B; A4P49JAZ9H / Ofloxacin
  •  go-up   go-down


43. Theoulakis P, Goldblum D, Zimmerli S, Muehlethaler K, Frueh BE: Keratitis resulting from Thielavia subthermophila Mouchacca. Cornea; 2009 Oct;28(9):1067-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically, the organism appeared to respond to topical amphotericin B and oral voriconazole.
  • CONCLUSIONS: A rare case of Thielavia sp. keratitis was successfully treated with topical amphotericin B and oral voriconazole.
  • [MeSH-minor] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Child. Drug Therapy, Combination. Female. Humans. Pyrimidines / therapeutic use. Retrospective Studies. Triazoles / therapeutic use. Voriconazole

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19724200.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 7XU7A7DROE / Amphotericin B; JFU09I87TR / Voriconazole
  •  go-up   go-down


44. Rautemaa R, Richardson M, Pfaller M, Perheentupa J, Saxen H: Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole. Scand J Infect Dis; 2008;40(11-12):904-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These results highlight that also topical compounds, in particular miconazole, may influence fluconazole susceptibility.
  • Our data indicate that discretion should be used in the long-term use of all azoles, including topical miconazole.
  • At the same time topical amphotericin B appears to be a safe choice as resistance is very rare despite y of usage.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18651265.001).
  • [ISSN] 0036-5548
  • [Journal-full-title] Scandinavian journal of infectious diseases
  • [ISO-abbreviation] Scand. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antifungal Agents; 7NNO0D7S5M / Miconazole; 8VZV102JFY / Fluconazole; R9400W927I / Ketoconazole
  •  go-up   go-down


45. Cohen-Ludmann C, Kerob D, Feuilhade M, Chaine B, Guermazi A, Janier M, Levy A, Verola O, Morel P, Lebbe C, Lacroix C: Zygomycosis of the penis due to Rhizopus oryzae successfully treated with surgical debridement and a combination of high-dose liposomal and topical amphotericin B. Arch Dermatol; 2006 Dec;142(12):1657-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zygomycosis of the penis due to Rhizopus oryzae successfully treated with surgical debridement and a combination of high-dose liposomal and topical amphotericin B.
  • [MeSH-major] Amphotericin B / administration & dosage. Debridement / methods. Penile Diseases / therapy. Rhizopus / isolation & purification. Zygomycosis / therapy

  • Genetic Alliance. consumer health - Zygomycosis.
  • MedlinePlus Health Information. consumer health - Penis Disorders.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179006.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


46. Weschta M, Rimek D, Formanek M, Podbielski A, Riechelmann H: Effect of nasal antifungal therapy on nasal cell activation markers in chronic rhinosinusitis. Arch Otolaryngol Head Neck Surg; 2006 Jul;132(7):743-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTERVENTIONS: Nasal treatment with amphotericin B or saline control for 8 weeks.
  • Nasal amphotericin B treatment had no effect on levels of ECP (P = .17) or tryptase (P = .09) in nasal lavage samples.
  • CONCLUSION: Neither topical amphotericin B therapy nor fungal state before and after treatment had any significant influence on activation markers of nasal inflammatory cells in chronic rhinosinusitis.
  • [MeSH-major] Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Nasal Polyps / drug therapy. Rhinitis / drug therapy. Sinusitis / drug therapy

  • MedlinePlus Health Information. consumer health - Sinusitis.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847182.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down






Advertisement